Last reviewed · How we verify
VEE TC-83
At a glance
| Generic name | VEE TC-83 |
|---|---|
| Sponsor | U.S. Army Medical Research and Development Command |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase 1 Study Evaluating the Safety, Tolerability, and Immunogenicity of V4020 Vaccine in Healthy Volunteers (PHASE1)
- Safety and Immunogenicity Study of Venezuelan Equine Encephalomyelitis (VEE) Vaccine as Booster Vaccine in Adults (PHASE2)
- Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine in Healthy Adults (PHASE2)
- Safety and Immunogenicity of Venezuelan Equine Encephalomyelitis Vaccine (VEE C-84) as a Booster to VEE TC-83 (PHASE2)
- Safety and Immunogenicity Study of the Venezuelan Equine Encephalomyelitis Vaccine (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VEE TC-83 CI brief — competitive landscape report
- VEE TC-83 updates RSS · CI watch RSS
- U.S. Army Medical Research and Development Command portfolio CI